Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $23.38 USD
Change Today -0.43 / -1.81%
Volume 722.9K
QDEL On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

12544 High Bluff Drive

Suite 200

San Diego, CA 92130

United States

Phone: 858-552-1100

Fax: 858-453-4338

Quidel Corporation engages in the development, manufacture, and marketing of diagnostic testing solutions for applications in infectious diseases, women’s health, and gastrointestinal diseases. The company’s diagnostic solutions aid in the detection and diagnosis of critical diseases and other medical conditions, including infectious diseases, women’s health, autoimmune diseases, bone health, thyroid diseases, and fecal occult blood. The company’s subsidiary, Diagnostic Hybrids, Inc. (DHI), a privately-held, in vitro diagnostics (IVD) company, is engaged in the manufacture and commercialization of U.S. Food and Drug Administration cleared direct fluorescent IVD assays used in hospitals and reference laboratories for various diseases, including certain viral infections and thyroid diseases. Business Strategy The company’s approach to address the diagnostic continuum relative to its strategy comprises three parts: rapid point of care immunoassay tests for use in physician offices, hospital laboratories and emergency departments, retail clinics, and other urgent care settings; direct fluorescent assays (DFA) and culture-based tests for the clinical virology laboratory; and molecular diagnostic tests across various laboratory segments. Products The company provides diagnostic testing solutions under various brand names, including among others, the following: QuickVue, QuickVue+, Quidel, MicroVue, FreshCells, D3 FastPoint, Super E-Mix, ELVIS, Sofia, Quidel Molecular, Amplivue, Lyra and Thyretain. The company’s diagnostic testing solutions address the following medical and wellness categories: System Platforms SofiaMAnalyzer: Sofia is the brand name for the company’s next generation fluorescent immunoassay (FIA) system. The Sofia FIA tests employ advanced lateral flow and immunofluorescence technologies to provide enhanced performance for assays. The Sofia Analyzer provides for different operational modes to accommodate both small and large laboratories, as well as other features designed to facilitate use in various healthcare settings, including hospitals, medical centers, and small clinics. Molecular assays The company’s open system assays run on various thermocyclers on the market, such as the Applied Biosystems 7500 Fast DX thermocycler, QuantStudio Dx or the Cepheid SmartCycler thermocycler. Infectious Diseases Influenza: The company’s Sofia Influenza A+B test, used in conjunction with its SofiaM Analyzer, and its QuickVue influenza tests are rapid, qualitative tests for the detection of the viral antigens of influenza type A and B, the two most common types of the influenza virus. In addition, its Sofia Influenza A+B test has special 510(k) clearance for an update to package insert to include analytical reactivity with an avian Influenza A (H7N9) strain, A/Anhui/1/2013. In addition, during 2013, the company began selling its Quidel Molecular Influenza A+B assay for use on the QuantStudio Dx Real-Time PCR Instruments by Life Technologies. Group A Strep: The company’s Sofia Strep A fluorescent immunoassay, used in conjunction with its SofiaM Analyzer, and its QuickVue Strep A tests are intended for the rapid, qualitative detection of Group A Streptococcal antigen from throat swabs or confirmation of presumptive Group A Streptococcal colonies recovered from culture. Also, in 2013, the company began selling its AmpliVue Group B Strep Assay. Respiratory Syncytial Virus (RSV) Test: The company’s Sofia RSV test and its QuickVue RSV test are rapid immunoassay tests for RSV. During 2013, the company also began selling its Quidel Molecular RSV + human metapneumovirus (hMPV) test, its Quidel Molecular Influenza A+B assay and the Quidel Molecular RSV + hMPV assay, both for use on the QuantStudio Dx Real-Time PCR Instruments by Life Technologies Corporation. Multiplex Respiratory: The company’s cell culture and DFA detection solutions are used by reference laboratories, public health labs and acute care hospitals to detect seven major viral respiratory pathogens. The company’s proprietary cell culture platform R-Mix combined with its FDA cleared antibody kit D3 Ultra DFA, detects Influenza

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
QDEL:US $23.38 USD -0.43

QDEL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Analogic Corp $88.06 USD -0.13
GenMark Diagnostics Inc $10.69 USD -0.24
Luminex Corp $16.10 USD -0.18
Meridian Bioscience Inc $19.13 USD +0.33
OraSure Technologies Inc $6.71 USD -0.09
View Industry Companies
 

Industry Analysis

QDEL

Industry Average

Valuation QDEL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.1x
Price/Book 3.3x
Price/Cash Flow 111.2x
TEV/Sales 2.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QUIDEL CORP, please visit www.quidel.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.